BioSpace News Archive

Mirum Pharmaceuticals, Inc. announced that on September 8, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 174,000 shares of common stock and 91,000 restricted stock units to 21 new employees under Mirum’s 2020 Inducement Plan.

Mabwell, an innovative biopharmaceutical company with entire industry chain, and WuXi XDC, a leading global CRDMO, joint announced that they have signed a LOI for long-term strategic collaboration on Mabwell’s multiple ADC projects.

Adrenomed AG, the vascular integrity company, announced new findings on the biomarker-guided treatment of septic shock with enibarcimab.

Grit Biotechnology announced the completion of a Series B financing round, raising over 60 million USD.

NMD Pharma A/S, a clinical-stage biotech company developing first-in-class, small molecule ClC-1 inhibitors for neuromuscular disorders, today announces that it will be hosting a satellite symposium and presenting new data from a Phase I/IIa clinical trial of NMD670 in patients with myasthenia gravis (MG) at the conference.

OKYO Pharma Limited is pleased to announce that it has completed full enrollment of patients in the randomized portion of the Phase 2 multi-center, double-masked, placebo-controlled clinical trial of topical ocular OK-101 to treat DED. A total of 240 patients have been enrolled in the study.

Tiziana Life Sciences Ltd. today announced that the Company will virtually present and host one-on-one meetings at the H.C. Wainwright 25th Annual Global Investment Conference, being held September 11-13, 2023.

NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”) today issued the following statement regarding the Schedule 13D filed with the U.S. Securities and Exchange Commission on August 31, 2023, by Symetryx Corporation (“Symetryx”) and their subsequent press release issued on September 6, 2023.

BriaCell Therapeutics Corp. today announces the completion of patient enrollment in its Phase 2 clinical study and reports clinical data showing strong patient survival benefit and clinical benefit in advanced metastatic breast cancer patients.

Aditxt, Inc. (NASDAQ: ADTX) Announces Participation at the H.C. Wainwright 25th Annual Global Investment Conference September 11th -13th , 2023.